SII is pursuing approval for the Covishield as a booster dose due to concerns of Omicron

Bharat Biotech has submitted Covaxin's Phase III trial data to DCGI: Govt sources

The Hyderabad-based COVID vaccine manufacturing company Bharat Biotech submitted data from the Phase III clinical trials of Covaxin

First batch of drug 2-DG expected to be launched next week for COVID patients

DCGI allows Phase II-III clinical trial of Covaxin on 2 to 18-years-old

Regulator gives nod to emergency use of DRDO's Anti-Covid drug, that will come in powder form

Serum Institute seeks emergency authorisation for Covid-19 vaccine in India

<p>The Serum Institute of India (SII) on Sunday became the first indigenous company to apply to the Drugs Controller General of India (DCGI) seeking emergency use authorisation (EUA) for the Oxford Covid-19 vaccine in the country, official sources said. A day earlier, the Indian arm of US pharmaceutical giant Pfizer became the first to seek […]</p>